BeiGene, Ltd. (ONC : NASDAQ)
Common Stock
$362.78
USD
+1.13 (0.31%)
Last updated: 2026-10-06
Follow ONC
ONC
BeiGene, Ltd.
WealthAwesomePerformance
1 Day
+0.31%
1 Week
-0.68%
1 Month
+1.26%
YTD
+16.64%
Key Statistics
Market Cap
$41.27B
52W High
$385.22
52W Low
$253.95
P/E Ratio
64.90
50 Day MA
$354.02
200 Day MA
$320.38
Beta
0.61
Dividend Yield
-
Advertisement
Technical Indicators
Price vs 50-Day SMA
Price vs 200-Day SMA
Recent Price History
| Date | Open | High | Low | Close | Adj Close | Volume |
|---|---|---|---|---|---|---|
| 10/6/2026 | $365.13 | $368.40 | $359.10 | $362.78 | $362.78 | 211,753 |
| 10/5/2026 | $362.48 | $362.83 | $356.82 | $361.65 | $361.65 | 210,698 |
| 10/2/2026 | $351.01 | $358.57 | $349.74 | $358.07 | $358.07 | 505,200 |
| 10/1/2026 | $367.94 | $371.09 | $358.32 | $358.77 | $358.77 | 351,400 |
| 9/30/2026 | $370.00 | $376.50 | $365.79 | $365.94 | $365.94 | 328,900 |
| 9/29/2026 | $362.76 | $367.43 | $357.17 | $365.27 | $365.27 | 372,800 |
| 9/28/2026 | $360.42 | $368.05 | $358.00 | $367.00 | $367.00 | 350,500 |
| 9/25/2026 | $362.51 | $365.00 | $358.51 | $360.85 | $360.85 | 377,200 |
| 9/24/2026 | $355.37 | $361.12 | $354.94 | $359.97 | $359.97 | 472,800 |
| 9/23/2026 | $362.50 | $365.70 | $361.31 | $365.00 | $365.00 | 631,800 |
Analyst Price Targets
Based on analyst covering ONC · as of Oct 5, 2026
Wall Street analysts forecast ONC stock price to rise 19.5% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
US$433.52
+19.5% Upside
Current Price
US$362.78
Last close
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on ONC's historical volatility
30-Day Vol
23.5%
Annualized
90-Day Vol
28.4%
Annualized
Trend (90d)
+50.0%
Annualized drift
90d Mean
US$433.71
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | US$385.03 | US$355.05 – US$417.55 |
| 60 trading days | US$408.64 | US$364.38 – US$458.29 |
| 90 trading days | US$433.71 | US$376.89 – US$499.09 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
About BeiGene, Ltd.
BeOne Medicines AG, an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company's commercial stage products include BRUKINSA, a small molecule inhibitor of Bruton's Tyrosine Kinase (BTK) for the treatment of various blood cancers; TEVIMBRA, an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; SYLVANT for the treatment of adult patients with multicentric castleman disease; BAITUOWEI for patients with BC in premenopausal and perimenopausal women, and cancer; and PARTRUVIX for the treatment of various solid tumors. Its clinical stage products comprise Sonrotoclax BGB-11417, a small molecule Bcl-2 inhibitor; BGB-16673, a BTK targeting chimeric degradation activation compound active against wild type and mutant BTK; BG-60366, an EGFR-targeted CDAC; BG-89894 (SYH2039), a MAT2A Inhibitor; BGB-58067, an MTA-Cooperative PRMT5 Inhibitor; BG-T187 and BG-C0902, an anti-EGFRxMET trispecific antibody; BGB-26808, a HPK-1 Inhibitor; BGB-C354, an anti-B7H3 ADC; Zanidatamab, a bispecific HER2-targeted antibody; BG-C137, an anti-FGFR2b ADC; BGB-53038, a Pan-KRAS Inhibitor; BGB-B2033, an anti-GPC3x4-1BB bispecific antibody; BGB-B3227, an anti-MUC1xCD16A bispecific antibody; BG-C477, an anti-CEAADC; BGB-43395, a CDK4 Inhibitor; BG-68501, a CDK2 Inhibitor; BG-C9074, an anti-B7H4 ADC; BGB-21447, a Bcl-2 Inhibitor; and BGB-45035, an IRAK4-targeted CDAC. It also has various preclinical programs. The company has agreements Amgen, BMS, Bio-Thera, EUSA Pharma, Luye Pharmaceutical, and Novartis. The company was formerly known as BeiGene, Ltd. and changed its name to BeOne Medicines AG in May 2025. The company has a agreement with U.S. government to expand access to innovative cancer medicines. BeOne Medicines AG was founded in 2010 and is based in Basel, Switzerland.
Financials
- Revenue (TTM)
- $6.13B
- EBITDA
- $1.07B
- Profit Margin
- 10.70%
- ROE (TTM)
- 14.66%
- EPS (Diluted)
- 5.59
- Book Value
- 45.78
Classification
- Sector
- Health Care
- Industry
- Biotechnology
- Group
- Pharmaceuticals, Biotechnology & Life Sciences
7 stocks to buy and hold forever
Blue-chip dividend stocks for long-term wealth building.
Get the FREE ReportExplore More
Advertisement
Common Questions About ONC.US
Market movers
Recent NASDAQ movers
Top 1-day gainers — updated from our Canadian movers feed.
| Ticker | Name | Price | 1D |
|---|---|---|---|
| QRVO | Qorvo Inc | $2070.39 | +1713.43% |
| SUGP | SU Group Holdings Limited Ordinary Shares | $2.44 | +511.43% |
| COLA | Columbus Acquisition Corp Ordinary Shares | $5.16 | +178.92% |
| OLB | OLB Group Inc | $0.41 | +117.85% |
| MOBX | Mobix Labs Inc | $1.12 | +72.28% |
| VCIG | VCI Global Limited Ordinary Share | $1.41 | +54.77% |
| XHLD | TEN Holdings, Inc. Common Stock | $0.62 | +51.58% |
| IPDN | Professional Diversity Network Inc | $4.61 | +48.71% |
ONC.US news timeline
1 article covering ONC.US, most recent first
Latest